High expression of epidermal growth factor receptor might predict poor survival in patients with colon cancer: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 4, 2013, Pages 348-351

  Hong, Liu ^a   Han, Yu ^a   Zhang, Hongwei ^a   Zhao, Qingchuan ^a   Yang, Jianjun ^a   Ahuja, Nita ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLON CANCER; ETHNICITY; HUMAN; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; SURVIVAL RATE; SYSTEMATIC REVIEW;

COLONIC NEOPLASMS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; UP-REGULATION;

EID: 84875666371     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0421     Document Type: Article

References (24)

1. Andersen JB, Spee B, Blechacz BR, et al. (2012) Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142:1021-1031.
2. De Gramont A, Chibaudel B, Bachet JB, et al. (2011) From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol 38:521-532.
3. Galizia G, Lieto E, Ferraraccio F, et al. (2006) Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 13:823-835.
4. Hong L, Li S, Han Y, et al. (2011) Angiogenesis-related molecular targets in esophageal cancer. Expert Opin Investig Drugs 20:637-644.
5. Hong L, Han Y, Li S, et al. (2012) The malignant phenotypeassociated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther 10:1693-1701.
6. Janmaat ML, Giaccone G (2003) The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc) 39 (Suppl C):61-80.
7. Khorana AA, Ryan CK, Cox C, et al. (2003) Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 97:960-968.
8. Ljuslinder I, Melin B, Henriksson ML, et al. (2011) Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer. Int J Cancer 128:2031-2037.
9. Laurent-Puig P, Cayre A, Manceau G, et al. (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924-5930.
10. Loupakis F, Cremolini C, Salvatore L, et al. (2012) Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. Cancer 118:1523-1532.
11. Lin AY, Buckley NS, Lu AT, et al. (2011) Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. Clin Colorectal Cancer 10:63-69.
12. Luo G, Long J, Qiu L, et al. (2011) Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. Pancreatology 11:595-600.
13. Ohchi T, Akagi Y, Kinugasa T, et al. (2012) Amphiregulin is a prognostic factor in colorectal cancer. Anticancer Res 32:2315- 2321.
14. Press OA, Zhang W, Gordon MA, et al. (2008) Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res 68:3037-3042.
15. Petrelli F, Borgonovo K, Cabiddu M, et al. (2012) Risk of anti- EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf 11 (Suppl 1):S9-S19.
16. Patel BB, Gupta D, Elliott AA, et al. (2010) Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 30:319-325.
17. Rego RL, Foster NR, Smyrk TC, et al. (2010) Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 102:165-172.
18. Rinella ES, Bankaitis ED, Threadgill DW (2012) Dietary calcium supplementation enhances efficacy but also toxicity of EGFR inhibitor therapy for colon cancer. Cancer Biol Ther 13:130-137.
19. Rousseau B, Chibaudel B, Bachet JB, et al. (2010) Stage II and stage III colon cancer: treatment advances and future directions. Cancer J 16:202-209.
20. Winder T, Lenz HJ (2010) Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev 36:550-556.
21. Ren JH, He WS, Yan GL, et al. (2012) EGFR mutations in nonsmall- cell lung cancer among smokers and non-smokers: a meta-analysis. Environ Mol Mutagen 53:78-82.
22. Sia D, Villanueva A (2011) Signaling pathways in hepatocellular carcinoma. Oncology 81:18-23.
23. Saif MW (2006) Targeted agents for adjuvant therapy of colon cancer. Clin Colorectal Cancer 6:46-51.
24. Yasuda H, Tanaka K, Saigusa S, et al. (2009) Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncol Rep 22:709-717.